Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy

Molecular Cancer Research

Volumn 7, Issue 2, 2009, Pages 199-209

  Horne, Hisani N ^a   Lee, Paula S ^b   Murphy, Susan K ^a,b   Alonso, Miguela ^c   Olson Jr , John A ^a   Marks, Jeffrey R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; BISULFITE; MYELIN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL MOTILITY; CELL STRAIN MCF 7; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPID RAFT; MAJOR CLINICAL STUDY; MUTATION; MYELIN AND LYMPHOCYTE GENE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR GENE;

AZACITIDINE; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE; CELL MOVEMENT; CHEMOTHERAPY, ADJUVANT; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; LASERS; MEMBRANE MICRODOMAINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYELIN PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEOLIPIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; WOUND HEALING;

EID: 61349185802     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0314     Document Type: Article

References (32)

1. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Int Med 2001;134:573-86.
2. Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer Lett 2004;211:133-43.
3. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004;10:6189-93.
4. Momparler RL. Cancer epigenetics. Oncogene 2003;22:6479-83.
5. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997;272:22322-9.
6. Tomatsu S, Orii KO, Islam MR, et al. Methylation patterns of the human β-glucuronidase gene locus: boundaries of methylation and general implications for frequent point mutations at CpG dinucleotides. Genomics 2002;79:363-75.
7. Alonso MA, Weissman SM. cDNA cloning and sequence of MAL, a hydrophobic protein associated with human T-cell differentiation. Proc Natl Acad Sci U S A 1987;84:1997-2001.
8. Martin-Belmonte F, Kremer L, Albar JP, Marazuela M, Alonso MA. Expression of the MAL gene in the thyroid: the MAL proteolipid, a component of glycolipid-enriched membranes, is apically distributed in thyroid follicles. Endocrinology 1998;139:2077-84.
9. Millan J, Alonso MA. MAL, a novel integral membrane protein of human T lymphocytes, associates with glycosylphosphatidylinositol-anchored proteins and Src-like tyrosine kinases. Eur J Immunol 1998;28:3675-84.
10. Zacchetti D, Peranen J, Murata M, Fiedler K, Simons K. VIP17/MAL, a proteolipid in apical transport vesicles. FEBS Lett 1995;377:465-9.
11. Cheong KH, Zacchetti D, Schneeberger EE, Simons K. VIP17/MAL, a lipid raft-associated protein, is involved in apical transport in MDCK cells. Proc Natl Acad Sci U S A1999;96:6241 -8.
12. Martin-Belmonte F, Puertollano R, Millan J, Alonso MA. The MAL proteolipid is necessary for the overall apical delivery of membrane proteins in the polarized epithelial Madin-Darby canine kidney and Fischer rat thyroid cell lines. Mol Biol Cell 2000;11:2033-45.
13. Marazuela M, Acevedo A, Adrados M, Garcia-Lopez MA, Alonso MA. Expression of MAL, an integral protein component of the machinery for raft- mediated apical transport, in human epithelia. J Histochem Cytochem 2003;51:665-74.
14. Alonso MA, Millan J. The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J Cell Sci 2001;114:3957-65.
15. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96.
16. Bickel PE, Scherer PE, Schnitzer JE, Oh P, Lisanti MP, Lodish HF. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem 1997;272:13793-802.
17. Martin-Belmonte F, Arvan P, Alonso MA. MAL mediates apical transport of secretory proteins in polarized epithelial Madin-Darby canine kidney cells. J Biol Chem 2001;276:49337-42.
18. Mimori K, Shiraishi T, Mashino K, et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003;22:3463-71.
19. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 2006;131:797-808.
20. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev 2002;3:415-28.
21. Tugores A, Rubio T, Rancano C, Alonso MA. A tandem array of Sp-1 sites and a reverse initiator element are both required for synergistic transcriptional activation of the T-cell-specific MAL gene. DNA Cell Biol 1997;16:245 -55.
22. Wei M, Grushko TA, Dignam J, et al. BRCA1promoter methylation in sporadic breast cancer is associated with reduced BRCA1copy number and chromosome 17 aneusomy. Cancer Res 2005;65:10692-9.
23. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
24. Hatta M, Nagai H, Okino K, et al. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. J Obstet Gynaecol Res 2004;30:53 -8.
25. Marazuela M, Alonso MA. Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue. Histol Histopathol 2004;19:925-33.
26. Tracey L, Villuendas R, Ortiz P, et al. Identification of genes involved in resistance to interferon-α in cutaneous T-cell lymphoma. Am J Pathol 2002;161:1825-37.
27. Hsi ED, Sup SJ, Alemany C, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol 2006;125:776-82.
28. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001;29:E65-5.
29. Huang Z, Wen Y, Shandilya R, Marks JR, Berchuck A, Murphy SK. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res 2006;34:555 -63.
30. Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci U S A 1990;87:463 -7.
31. Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene 1996;13:1315-22.
32. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid- enriched membrane subdomains during transport to the apical cell surface. Cell 1992;68:533 - 44.